Quillin Highlights Arthrex Decision as Key Patent Ruling of 2021 for Law360
July 6, 2021
Law360
Partner George E. Quillin was quoted in Law360’s first half recap of the key patent rulings and decisions in 2021, “The Biggest Patent Rulings Of 2021: A Midyear Report,” highlighting the importance of the high court’s ruling on the Patent Trial and Appeal Board process.
On the significance of U.S. vs. Arthrex decision, George said, “The court’s remedy requires only that the director have the discretion to decide whether or not he will rehear any of the IPRs. The cynic can imagine a busy bureaucrat’s easy choice on such a decision.”
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.